Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2014 Apr 1;20(7):1721-3.
doi: 10.1158/1078-0432.CCR-14-0056. Epub 2014 Mar 14.

Seeing the forest for the trees: kidney oncogenomes in relation to therapeutic outcomes

David D Chism  1 , W Kimryn Rathmell
Affiliations
Comment

Seeing the forest for the trees: kidney oncogenomes in relation to therapeutic outcomes

David D Chism et al. Clin Cancer Res. .

Abstract

Renal cell carcinoma is a heterogeneous disease, and tissue investigations provide clues that may predict treatment response. Oncogenomic analysis of five outliers, who achieved a sustained response with rapalogs, implicates alterations of the TSC1 and mTOR genes and reveals insights into the conserved evolution of tumors.

PubMed Disclaimer

Conflict of interest statement

Dislcosure of potential conflicts of Interest: Research support and collaboration, including support for sabbatical, from Novartis (spouse of WKR).

Figures

Figure 1
Figure 1. Concordance of mTOR pathway activating mutations confers rapalogue sensitivity
Patient 2 has an early “trunk” event in all regions (R1, R2 and R3 respectively) of the primary clear cell renal cell carcinoma (ccRCC) tumor and its metastases (M1); Patient 3 demonstrates a late “branch” mutation in two different regions (R1,R3 vs. R3,R4 respectively) of the primary ccRCC tumor.
See this image and copyright information in PMC

Comment on

References

    1. Voss MH, Hakimi AA, Pham CG, Brannon AR, Chen YB, Cunha LF, et al. Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapy. Clin Cancer Res. 2014;116:4696–702. - PMC - PubMed
    1. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature. 499:43–9. - PMC - PubMed
    1. La Rochelle J, Klatte T, Dastane A, et al. Chromosome 9p deletions identify an aggressive phenotype of clear cell renal cell carcinoma. Cancer. 116:4696–702. - PubMed
    1. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 366:883–92. - PMC - PubMed
    1. Abou Youssif T, Fahmy MA, Koumakpayi IH, et al. The mammalian target of rapamycin pathway is widely activated without PTEN deletion in renal cell carcinoma metastases. Cancer. 117:290–300. - PubMed

Publication types

MeSH terms

Substances